Time-restricted eating for patients with moderate chronic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of time-restricted eating (TRE) on proteinuria, glomerular filtration rate decline, and weight loss in patients with moderate chronic kidney disease (CKD) and albuminuria. Participants will follow a 12-hour eating window, and their dietary habits will be monitored using a smartphone app. The goal is to understand how this dietary approach can impact the progression of CKD and improve metabolic health in affected individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical criteria

  * Adult men and women
  * Chronic Kidney Disease with KDIGO stage G2 and G3 defined by a Glomerular Filtration Rate between 30 and 90 mL/min/1.73m2
  * Albuminuria stage A2 or A3, but without nephrotic-range proteinuria: 3 to 200 mg/mmol
  * Body mass index 18-40 kg/m2
  * Eating window of 12 hours (self-reported and measured during the run-in phase)
* Study-related criteria

  * Able to give informed consent and follow the study procedures for the entire duration
  * Confident use of a smartphone compatible with the MyFoodRepo app (iOS, Android) and able to take regular pictures of food/drinks

Exclusion Criteria:

* Clinical criteria

  * Pregnant and breastfeeding women, plans for maternity during the study
  * Eating disorder(s)
  * Other diets: low-carb, ketogenic diet, hypocaloric diets (eviction for food intolerances, vegan/vegetarian diet are not excluded)
  * Uncontrolled blood pressure (\> 160/100 mmHg)
  * Diabetes with hypoglycemic drug(s) will be excluded, however those with impaired glucose tolerance (prediabetes, as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included
  * Oral corticosteroids
  * Uncontrolled diabetes HbA1c \> 8.5%
  * Active cancer and/or oncologic treatment over the previous 12 months
  * Major mental illness
  * Consumption of \> 7 standard units of alcohol per week for women and \> 14 standard units of alcohol per week for men
  * Shift work, such as evening shifts or night shifts planned during the study
  * Travel/trip to a different time zone (≥ 2-hour time difference) planned during the study
* Study-related criteria and other interventions

  * Recent treatment modification in the last 3 months, including but not limited to ACE blockers, SLGT2i, finerenone
  * Patients with recent glomerulonephritis diagnosis on more than 2 immunosuppressive drugs
  * Patients with kidney transplant in the last past year
  * Enrolled in another interventional clinical trial (medication, medical device) over the previous 1 month and planned during the study

Where it's running

• University Hospital, Geneva
  Geneva, Switzerland Recruiting

Study contacts

• Principal investigator: Sophie de Seigneux, MD, PhD — University Hospital, Geneva
• Study coordinator: Delal Dalga, MD, PhD
• Email: delal.dalga@unige.ch
• Phone: +41-22-3723311

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Living with CKD as a woman of childbearing age without dialysis or transplant

  This study asks how women aged 18 and up with chronic kidney disease, not on kidney replacement therapy, experience living with the condition.

  Recruiting University Hospital, Caen · Caen · NCT07690202

• Balcinrenone plus dapagliflozin vs dapagliflozin alone in CKD stages 3b-4

  This study tests whether balcinrenone combined with dapagliflozin works better than dapagliflozin alone in adults with CKD stage 3b–4.

  Recruiting at 33 sites Phase 3 AstraZeneca · Huntsville, Alabama and 477 other locations · NCT07624305

• Exercise during hemodialysis to prevent muscle loss and improve sleep

  This trial will test if a 12-week supervised exercise program performed during dialysis can improve muscle mass, strength, physical performance, sleep quality, and quality of life for patients aged 40 and over on chronic hemodialysis.

  Recruiting University of Salamanca · Salamanca, Salamanca · NCT07447375

• Home-based exercise to boost fitness for people waiting for a kidney transplant

  This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07446296

• Transformative 2.0 for diabetic kidney disease

  This project will try to see if adults with diabetic kidney disease who take SGLT2 diabetes medicines have different biological patterns in archived kidney tissue than similar people who do not take these medicines.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07444203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.